Parkinson's disease
Conditions
Interventions
Treatment group :Autologous olfactory mucosa mesenchymal stromal cell therapy + routine Parkinson's disease treatment
Control group:Placebo treatment plus routine Parkinson's disease treatment
Sponsors
The Second Affiliated Hospital of Hu'nan Normal University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 40-80 years, gender is not limited; 2. Patients currently diagnosed with Parkinson's disease with motor complications (diagnosed by a neurologist), meeting the diagnostic criteria for Parkinson's disease in China in 2016; 3. Sensitivity to levodopa, defined as at least a 33% improvement in the UPDRS motor score during the ''on'' period compared to the ''off'' period; 4. Hoehn-Yahr staging is between 1-5; 5. Head MRI does not suggest brain atrophy or other intracranial lesions; 6. Normal bone marrow hematopoietic function, no bleeding tendency, blood routine: HGB>=90g/L, WBC>4.0x10^9/L (NEU>=1.5x10^9/L), PLT>=100x10^9/L ; 7. Liver function: total bilirubin =80mL/min; 9. There is no evidence of acute inflammatory infection on chest CT; 10. No other serious heart, liver, kidney disease, etc.; 11. No serious viral or bacterial infection; 12. Patients or legal representatives agree to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Highly allergic or have a history of severe allergies; 2. Those with mental or psychological diseases who cannot cooperate with treatment and efficacy evaluation; 3. Patients with systemic infection or severe local infection requiring anti-infective treatment; 4. Coagulation disorders (such as hemophilia); 5. Infectious diseases (such as HIV, RPR, active tuberculosis, etc.); 6. Patients with severe autoimmune diseases; 7. The investigator believes that there are other reasons for not being included in the treatment; 8. Received clinical research of other drugs within 3 months before screening; 9. Those who cannot comply with the research requirements; 10. Pregnant or lactating patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dopamine Transporter Brain Imaging;Unified Parkinson's Disease Rating Scale; | — |
Countries
China
Contacts
Public ContactZhuo Yi
The Second Affiliated Hospital of Hu'nan Normal University
Outcome results
None listed